Psychiatric Times

11/10/2025

In a phase 2b open-label extension study of AtaiBeckley's BPL-003 in patients with treatment-resistant depression, investigators found that a 12 mg dose of BPL-003 administered 8 weeks after a 0.3 mg, 8 mg, or 12 mg dose of BPL-003 was generally well-tolerated and provided additional rapid, clinically meaningful antidepressant effects, which were sustained for up to 8 weeks.

AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.

11/07/2025

📢 CALL FOR PAPERS: Submit articles, 1000 to 1800 words in length, on use of the PRiSM instrument in research or clinical practice by January 31, 2026. See full guidelines here:

Submit to our writing contest for the opportunity to win publication in Psychiatric Times and a $500 prize!

11/07/2025

What increases the risk for ADHD?
Panelists examine the genetic, environmental, and socioeconomic factors that shape ADHD risk and what clinicians need to know. Watch now: https://hubs.li/Q03B6cc40

11/06/2025

The FDA has approved lumateprone (Caplyta) as an adjunctive therapy for the treatment of adults with major depressive disorder.

Johnson & Johnson's Caplyta gains FDA approval as an adjunctive treatment for major depressive disorder, offering hope for improved patient outcomes.

11/05/2025

The Stuttering Treatment and Research Society (STARS) is reshaping how the medical community understands stuttering.

As the first nonprofit dedicated to advancing neuroscience-based research and treatment for stuttering, STARS is uncovering the neurological foundations of stuttering while working to reduce stigma and improve access to care.

By uniting psychiatry, neurology, and speech-language pathology, STARS is driving meaningful progress for individuals who stutter.

11/04/2025

🚨New supplemental NDA submitted to the FDA: dextromethorphan-bupropion (AXS-05) for the treatment of Alzheimer disease agitation. https://www.psychiatrictimes.com/view/snda-submitted-for-axs-05-for-the-treatment-of-alzheimer-disease-agitation

11/03/2025

Our November theme: Best Practices.

If you are interested in potentially being featured in our print issue, submit to our content series! https://www.psychiatrictimes.com/view/presenting-our-november-theme-best-practices

10/31/2025

🎃 Happy Halloween! Explore the psychological meanings behind Halloween symbols, from ghosts to jack-o'-lanterns.

Explore the psychological meanings behind Halloween symbols, from ghosts to jack-o'-lanterns, and uncover their deeper significance in our lives.

10/31/2025

Mindfulness… even on a Friday full of monsters. 👻
Wishing you a mentally healthy and happy Halloween!

10/30/2025

Nutriband announced a successful feedback meeting with the FDA regarding their abuse deterrent fentanyl patch. The patch's proposed indication is pain management for patients with op**te tolerance who require daily and constant long term op**te treatment.

Nutriband engages with the FDA on its innovative abuse-deterrent fentanyl patch, paving the way for safer pain management solutions.

10/29/2025

Today is .

Understanding what lies ahead in the road to stroke recovery can help patients and their families prepare for the challenges they will face. Learn more here: https://www.psychiatrictimes.com/view/beyond-survival-understanding-the-long-road-to-stroke-recovery

10/28/2025

According to new positive phase 3 results, CTx-1301 for the treatment of pediatric ADHD delivered rapid onset of effect and sustained efficacy through the evening hours. https://www.psychiatrictimes.com/view/positive-phase-3-results-ctx-1301-for-the-treatment-of-pediatric-adhd